8-K 1 oig8k.txt OIG 8-K 81895-1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: November 8, 2002 Express Scripts, Inc. -------------------------------------------------------------------------------- (Exact Name of Registrant as specified in its Charter) Delaware 0-20199 43-1420563 -------------------------------------------------------------------------------- (State or other jurisdiction (Commission File No.) (I.R.S. Employer of corporation) Identification No.) 13900 Riverport Drive, Maryland Heights, Missouri 63043 -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (314) 770-1666 ----------------------------- -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) Item 9. Regulation FD Disclosure As previously disclosed, on August 6, 2002 Express Scripts, Inc.(the "Company") received a subpoena duces tecum issued by the Defense Criminal Investigative Service (DCIS) of the Office of Inspector General of the Department of Defense. This subpoena sought information pertaining to the purchase of Lipitor, a cholesterol-reducing drug, from Parke-Davis, Incorporated, Warner Lambert Company and Pfizer, Inc. for sale to the TRICARE program, a Department of Defense health care program. The Company has recently been advised by DCIS that it is no longer necessary for the Company to respond to this subpoena. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EXPRESS SCRIPTS, INC. Date: November 8, 2002 By: /s/ Barrett A. Toan _______________________________ Barrett A. Toan Chairman and Chief Executive Officer